TWITTER

• Making innovative PM technology more accessible in the European Union 

• Patients are at the centre of the health care process and should be more actively involved in the Health Technology Assessments (HTA)

• Adapting HTA to the new paradigm of personalised medicine

• Prices that reflect a different value in different indications

• Coordination assessment and reimbursement mechanisms for drugs and diagnostics

• Post-launch value assessments: addressing uncertainty where it matters most

• EU Member States should establish efficient data collection infrastructure to monitor utilisation, effectiveness and other quality of care in considerations of PM technology and services under routine care conditions.

• Effectives forms of utilisation management to address the inherent complexity of PM technologies and services